Spark Plug Pipe

HENDERSON, NV / ACCESSWIRE / November 27, 2018 / With the market in a bit of a swoon, many companies with positive 3rd quarter announcements have not yet seen them baked into the share price properly. Baron Rothschild’s famous quote “Buy when there’s blood in the street” may apply to companies that have experienced heavy selling despite very impressive news. Here are a few such companies to radar for a bounce. This applies to several sectors as well including biotech and cannabis stocks.

Today we are highlighting: Delcath Systems, Inc. (DCTH), Northwest Biotherapeutics, Inc. (OTCQB:NWBO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Emerald Health Therapeutics, Inc. (EMHTF), and OrganiGram Holdings, Inc. (OTCQX:OGRMF).

One biotech with impressive 3rd quarter results we’re highlighting is, Delcath Systems, Inc. (DCTH) (Market Cap: $5.67M Share Price: $0.32) an interventional oncology company focused on the treatment of primary and metastatic liver cancers. A few highlights from their announcement include: treating the first patients in their amended Phase 3 clinical trial investigating metastatic ocular melanoma, raising $7 million, increasing revenue 20% Y/Y, being published in European Radiology, and that’s just a few of the impressive nuggets from the report.

Biotech in general looks ripe for a major comeback in the next few weeks, and DCTH could be a major beneficiary.

Another biotech in their Phase 3 trial is already up quite a bit is, Northwest Biotherapeutics, Inc. (NWBO) (Market Cap: $139.78M Share Price: $0.27). The company is developing DCVax® personalized immune therapies for solid tumor cancers. The company has been on a nice run lately and just announced updated blinded interim data from the Phase 3 trial of DCVax®-L for Glioblastoma brain cancer were presented by Dr. Linda Liau at the 23rd Annual Meeting of the Society for Neuro-Oncology.

DCTH isn’t the only liver cancer play that has undergone a bit of a swoon despite strong news, Viking Therapeutics, Inc. (VKTX) (Market Cap: $833.22M Share Price: $11.66) a clinical-stage biopharma company focused on the development of novel therapies for metabolic and endocrine disorders announced the presentation of results from the company’s 12-week Phase 2 study of VK2809, its novel liver-selective thyroid receptor beta agonist, in patients with non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C).

As we noted above, like biotech, cannabis companies with positive news have been a bit beatdown as well, take, Emerald Health Therapeutics, Inc. (EMHTF), (Market Cap: $386.78M Share Price: $2.84) for instance. The company just received conditional approval of the TSX Venture Exchange regarding its 51:49 joint venture with San Diego-based Emerald Health Bioceuticals, to be called Emerald Health Naturals.

Another Canadian cannabis stock that has recently fell out of favor but is worth radaring includes, OrganiGram Holdings, Inc. (OGRMF) (Market Cap: $521.48M Share Price: $4.04) a leading licensed producer of cannabis for the medical and adult-use recreational markets.

Legal Disclaimer:

This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal Consulting has agreed to a twelve month term consulting agreement with DCTH dated 8/31/18. The agreement calls for $40,000 in cash, and 15,000 restricted 144 shares of DCTH per month. Issuer agreed to increase monthly cash payment in September to $120,000. All payments were made directly by Delcath Systems, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. DCTH was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.

http://www.regalconsultingllc.com/full legal disclaimer/

Microspeculators.com Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspecualtors.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

SOURCE: Regal Consulting, LLC